Keryx Bio (KERX) Announces Perifosine Phase 2 for Chronic and Small Lymphocytic Leukemia
More News related to KERX
- Stock Watch: InvestorSoup.com Issues Market Alert for Keryx Pharmaceuticals Inc.
- Morning Movers 12/02: ABCW, SNTS, BIOF, DYAX, SYMX Higher; HEB, PEIX Lower
- Skymark Research Initiates Independent Research Coverage on Keryx Biopharmaceuticals, Inc.
- AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
- Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401
More News related to Corporate News
- Unilever (UL) Recalls Slim-Fast RTD Products on Bacillus Cereus Contamination Possibility
- Rick’s Cabaret (RICK) to Buld New Club Near Dallas-Ft. Worth Int. Airport
- United Airlines (UAL) Reports RPMs Increased by 1.8% in November 2009
- SWS Group (SWS) Prices 4.35M Common Offering at $11.50/Share
- Celanese Corp. (CE) to Expand Flake and Tow Capacities in China
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
CLL is characterized by the accumulation of circulating B cells which are resistant to apoptosis.
Keryx is preparing to initiate a Phase 3 trial by year-end, under Special Protocol Assessment (SPA), for patients with advanced multiple myeloma.
Related Categories
Corporate NewsStocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
